To include your compound in the COVID-19 Resource Center, submit it here.

Benitec's BB-401 misses Stage 1 response threshold in Phase II for head and neck cancer

Benitec Biopharma Ltd. (ASX:BLT; NASDAQ:BNTC) said an initial analysis of the 12-patient Stage 1 cohort in a

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE